Insulet Reports First Quarter 2017 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod^® Insulin Management System (Omnipod System), today announced financial results for the three months ended March 31, 2017.

First Quarter Financial Highlights:

• First quarter revenue of $101.7 million exceeds the Company's guidance of $96 to $99 million and represents year-over-year growth of 25%.
  • U.S. Omnipod revenue of $59.7 million, an increase of 18%.
  • International Omnipod revenue of $25.1 million, an increase of 63%.
  • Drug Delivery revenue of $16.9 million, an increase of 12%.
• Gross margin of 58.4%, up 420 basis points, reflecting improved manufacturing and operational execution.